KURA vs DNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

KURA

59.5
AI Score
VS
KURA Wins

DNA

48.2
AI Score

Investment Advisor Scores

KURA

60score
Recommendation
HOLD

DNA

48score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric KURA DNA Winner
Revenue 61.98M 67.34M DNA
Net Income -211.88M -170.28M DNA
Net Margin -341.9% -252.9% DNA
Operating Income -226.48M -173.56M DNA
ROE -1179.7% -43.4% DNA
ROA -37.4% -18.0% DNA
Total Assets 566.50M 944.45M DNA
Cash 57.94M 84.50M DNA
Current Ratio 3.60 4.72 DNA
Free Cash Flow -204.08M -125.86M DNA

Relative Price Performance (Last 90 Days)

KURA 1M: -22.7% · 3M: -31.6% DNA 1M: -11.3% · 3M: +50.7%

Current Technical Phase

KURA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -9.2%), weak momentum, RSI 33

RSI (14): 33.0 · Price: $7.43

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 47.0 · Price: $10.23

Fundamentals Snapshot

Metric KURA DNA
Market Cap — —
Forward P/E -3.1 -3.5
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.1% -0.1%
Gross Margin -2.3% 0.7%
Operating Margin -3.9% -2.0%
EPS -3.30 -4.24
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, KURA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.